BCM
GRNA

Bridgeway Capital Management’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Bridgeway Capital Management’s Portfolio GRNA Stock Details GRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-145,000
Closed -$62.7K – 1476
2023
Q1 		$62.7K Buy
+145,000
New +$111K ﹤0.01% 1292

Other funds holding GRNA

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CGC
Continental Grain Company New York $366M AUM 0.18% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $119M AUM 87.46% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return

Bridgeway Capital Management's GRNA Position: Q2 2023 in Review

Bridgeway Capital Management sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q2 2023, closing a stake of 145,000 shares — an estimated $62.7K sold.

Bridgeway Capital Management first reported a position in GRNA in Q1 2023 and held it in 1 quarter. The position peaked at $62.7K in Q1 2023. 48 funds tracked by Wall St. Rank hold GRNA as of Q2 2023.

  • Bridgeway Capital Management reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q2 2023 after selling out during the quarter.
  • Bridgeway Capital Management sold 145,000 GreenLight Biosciences Holdings, PBC Common Stock shares in Q2 2023, an estimated $62.7K.
  • Bridgeway Capital Management first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q1 2023 and held it in 1 quarter.
  • Bridgeway Capital Management's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $62.7K in Q1 2023.
  • 48 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q2 2023.

Based on Bridgeway Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.